Joshua Reed
Chief Financial Officer (Departing)
Replay available
Aldeyra Therapeutics, Inc. (ALDX) Q1 2022 Earnings Call
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Q1 2022 earnings conference call, held 2022-05-05. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Todd Brady
President and Chief Executive Officer
Justin Kim
Analyst, Oppenheim
Mark Goodman
Analyst, SVB Leerink
Citi Analyst
Analyst, Citi
Kelly Shi
Analyst, Jefferies
Thomas Schrader
Analyst, BTIG
Matthew Cross
Analyst, Alliance Global Partners
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Aldeyra Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.069 -- 00:00:03.930 Ladies and gentlemen, thank you for standing by and welcome to the Eldera Therapeutics 00:00:03.930 -- 00:00:07.891 First Quarter 2022 Financial Results Conference Call. 00:00:07.891 -- 00:00:11.132 At this time, all participants are in a listen-only mode. 00:00:11.132 -- 00:00:15.054 After the speaker's presentation, there will be a question and answer session. 00:00:15.054 -- 00:00:18.975 I would now like to hand over the conference to Company's Chief Financial Officer, Mr. 00:00:18.975 -- 00:00:22.076 Joshua Reed. Please go ahead, sir. 00:00:22.076 -- 00:00:25.037 Good morning, everyone. With me today are Dr. 00:00:25.037 -- 00:00:30.186 Todd Brady, President and Chief Executive Officer, and Bruce Greenberg, incoming 00:00:30.186 -- 00:00:35.110 interim CFO. This morning we issued a press release reporting our financial results for 00:00:35.110 -- 00:00:37.860 the quarter end at March 31, 2022. 00:00:38.572 -- 00:00:43.757 A copy of the press release is available on the investors and media section of our website, 00:00:43.757 -- 00:00:45.757 www.aldera.com. 00:00:47.200 -- 00:00:51.043 Please note that this morning's conference call contains forward-looking statements regarding 00:00:51.043 -- 00:00:54.810 future events and the future performance of Aldera. 00:00:54.810 -- 00:00:58.911 Forward-looking statements include but are not limited to statements regarding submission 00:00:58.911 -- 00:01:04.152 of potential new drug applications, potential commercialization, the anticipated timing 00:01:04.152 -- 00:01:09.352 of results from our clinical trials, our projected cash runway, our possible 00:01:09.352 -- 00:01:14.353 or assumed future results of operations, expenses, and financial position, and 00:01:14.353 -- 00:01:17.113 p...